| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:AZ11657312 Free Base
CAS:804561-22-6
Package:25mg/RMB 10600;100mg/RMB 17500;50mg/RMB 13800
|
Tricyclo[3.3.1.13,7]decane-1-acetamide, N-[2-methyl-5-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-ylcarbonyl)phenyl]- manufacturers
|
| | Tricyclo[3.3.1.13,7]decane-1-acetamide, N-[2-methyl-5-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-ylcarbonyl)phenyl]- Basic information |
| | Tricyclo[3.3.1.13,7]decane-1-acetamide, N-[2-methyl-5-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-ylcarbonyl)phenyl]- Chemical Properties |
| Boiling point | 661.4±55.0 °C(Predicted) | | density | 1.231±0.06 g/cm3(Predicted) | | pka | 14.65±0.70(Predicted) |
| | Tricyclo[3.3.1.13,7]decane-1-acetamide, N-[2-methyl-5-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-ylcarbonyl)phenyl]- Usage And Synthesis |
| Description | AZ11657312 is a P2X7 receptor antagonist. AZ11657312 has been investigated as an anti-inflammatory treatment for conditions such as COPD, Crohn's disease and osteo- and rheumatoid arthritis. | | Uses | AZ11657312 is a P2X7 receptor antagonist with activity to restore stress natriuresis. AZ11657312 significantly increased renal medullary perfusion, only in mice treated with angiotensin II. AZ11657312 improves tissue oxygenation by blocking P2X7R, especially in areas of the kidney that are underoxygenated. Administration of AZ11657312 increased sodium excretion up to sixfold while normalizing blood pressure[1]. | | References | [1] Inhibition of the purinergic P2X7 receptor improves renal perfusion in angiotensin-II-infused rats |
| | Tricyclo[3.3.1.13,7]decane-1-acetamide, N-[2-methyl-5-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-ylcarbonyl)phenyl]- Preparation Products And Raw materials |
|